VELJKO MILETA POPOV
Medical Practice in Hanover, NH
License number
Pennsylvania MT193804
Category
Medicine
Type
Graduate Medical Trainee
Address
Address
2
Hanover, NH 03755
Pennsylvania
Pennsylvania
Personal information
See more information about VELJKO MILETA POPOV at radaris.comName
Address
Phone
150 Dorchester Rd, Lyme, NH 03768
16 Greensboro Rd, Hanover, NH 03755
304 Righter St, Philadelphia, PA 19128
Professional information
See more information about VELJKO MILETA POPOV at trustoria.com
Inhibitors Of Dihydrofolate Reductase With Antibacterial Antiprotozoal, Antifungal And Anticancer Properties
Inhibitors Of Dihydrofolate Reductase With Antibacterial Antiprotozoal, Antifungal And Anticancer Properties
US Patent:
2009010, Apr 23, 2009
Filed:
Jun 4, 2008
Appl. No.:
12/133099
Inventors:
Amy C. Anderson - Storrs CT, US
Dennis L. Wright - Storrs CT, US
Phillip M. Pelphrey - Williamsville NY, US
Tammy M. Joska - Hartford VT, US
Erin S.D. Bolstad - Vernon CT, US
David B. Bolstad - Vernon CT, US
Veljko Popov - Hanover NH, US
Dennis L. Wright - Storrs CT, US
Phillip M. Pelphrey - Williamsville NY, US
Tammy M. Joska - Hartford VT, US
Erin S.D. Bolstad - Vernon CT, US
David B. Bolstad - Vernon CT, US
Veljko Popov - Hanover NH, US
Assignee:
University of Connecticut - Farmington CT
International Classification:
A61K 31/505, C07D 239/42, A61P 31/04, A61P 31/10, A61P 33/02
US Classification:
514275, 544297
Abstract:
The compositions and methods described herein discloses the design, synthesis and testing of compounds that act as inhibitors of DHFR. The basic scaffold of these inhibitors includes a 2,4-diaminopyrimidine ring with a propargyl linker to another substituted aryl, bicyclo or heteroaryl ring. These DHFR inhibitors are potent and selective for many different pathogenic organisms, including the DHFR enzyme from bacteria such as and methicillin-resistant , fungi such as and and protozoa such as and . These compounds and other similar compounds are also potent against the mammalian enzyme and may be useful as anti-cancer therapeutics.